Pub Date : 2021-12-17DOI: 10.2174/2468187312666211217100726
S. P., A. Sailaja
Aim of the current study is to prepare and characterize sulfasalazine-loaded liposomes to improve the bioavailability of the drug and to lessen the adverse effects of the drug. Diseases like inflammatory bowel disease can be treated by anti-inflammatory agents like “Sulfasalazine,” It can also be used to treat ulcerative colitis and Crohn’s disease. The biological half-life of sulfasalazine is 5-10hr; as in the case of conventional therapy, there is a chance of missing the dose. Therefore, frequent administration of drugs is essential to maintain the desired steady-state level. The side effects are thrombocytopenia, megaloblastic anemia, bone marrow depression, folic acid deficiency, impairment of male fertility (Oligospermia), intestinal nephritis due to 5-ASA, diarrhoea, headache, and skin rashes. The bioavailability of sulfasalazine is 15%. This work was undertaken to enhance bioavailability and decrease the side effects. The main objective of the study is to improve the solubility of sulfasalazine by formulating a liposomal drug delivery system. The major objective is to develop a liposomal formulation with good stability and the highest entrapment efficiency. Liposomes were produced by the thin-film hydration method. Nine formulations of liposomes were prepared by varying the concentrations of soya lecithin and cholesterol and changing the drug ratio. The obtained liposomes were characterized for surface morphology, FTIR, particle size, zeta potential, drug content, entrapment efficiency, and in-vitro diffusion studies. Among the nine formulations of liposomes, F3 was found to be the best formulation with an entrapment efficiency of 97.8% and a zeta potential value of -37.2mV. Liposomes followed first-order kinetics with a non-fickian diffusion pathway. Sulfasalazine loaded liposomes were prepared with good stability and the highest entrapment efficiency.
{"title":"Formulation and Evaluation of Liposomal Drug Delivery System for Sulfasalazine","authors":"S. P., A. Sailaja","doi":"10.2174/2468187312666211217100726","DOIUrl":"https://doi.org/10.2174/2468187312666211217100726","url":null,"abstract":"\u0000\u0000Aim of the current study is to prepare and characterize sulfasalazine-loaded liposomes to improve the bioavailability of the drug and to lessen the adverse effects of the drug. \u0000\u0000\u0000\u0000\u0000 Diseases like inflammatory bowel disease can be treated by anti-inflammatory agents like “Sulfasalazine,” It can also be used to treat ulcerative colitis and Crohn’s disease. The biological half-life of sulfasalazine is 5-10hr; as in the case of conventional therapy, there is a chance of missing the dose. Therefore, frequent administration of drugs is essential to maintain the desired steady-state level. The side effects are thrombocytopenia, megaloblastic anemia, bone marrow depression, folic acid deficiency, impairment of male fertility (Oligospermia), intestinal nephritis due to 5-ASA, diarrhoea, headache, and skin rashes. The bioavailability of sulfasalazine is 15%. This work was undertaken to enhance bioavailability and decrease the side effects.\u0000\u0000\u0000\u0000\u0000The main objective of the study is to improve the solubility of sulfasalazine by formulating a liposomal drug delivery system. The major objective is to develop a liposomal formulation with good stability and the highest entrapment efficiency.\u0000\u0000\u0000\u0000\u0000Liposomes were produced by the thin-film hydration method. Nine formulations of liposomes were prepared by varying the concentrations of soya lecithin and cholesterol and changing the drug ratio. The obtained liposomes were characterized for surface morphology, FTIR, particle size, zeta potential, drug content, entrapment efficiency, and in-vitro diffusion studies.\u0000\u0000\u0000\u0000\u0000Among the nine formulations of liposomes, F3 was found to be the best formulation with an entrapment efficiency of 97.8% and a zeta potential value of -37.2mV. Liposomes followed first-order kinetics with a non-fickian diffusion pathway. \u0000\u0000\u0000\u0000\u0000Sulfasalazine loaded liposomes were prepared with good stability and the highest entrapment efficiency.\u0000\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48263024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.2174/2468187311666211201111858
Vaibhav Rajoriya, Varsha Kashaw, S. Kashaw
The current paper represents the development, optimization, and characterization of paclitaxel-loaded folate conjugated solid lipid nanoparticles (FA-SLNs). The ligand (FA-SLNs) conjugated and non-conjugated SLNs (PTX-SLNs) were prepared by hot homogenization method. Both of the formulations (FA-SLNs and PTX-SLNs) were optimized with various parameters i.e. drug loading, stirring time, stirring speed, particle size, and polydispersity index, and characterized. The in-vitro drug release study was performed in different pH environments by using the dialysis bag method. The surface morphology and particle size were determined through scanning electron micorscopy and Transmission Electron Microscopy respectively, The SLNs formulations were also evaluated for the stability study. The particle size of PTX-SLNs and FA-SLNs was determined and found to be 190.1±1.9 and 231.3±2.3 nm respectively. The surface morphology of the SLNs indicates that the prepared formulations are round-shaped and show smooth surfaces. The TEM study indicated that particles were in the range of 100-300 nm. The entrapment efficiency and drug loading capacity of FA-SLNs were found to be 79.42±1.6% and 17.3±1.9%, respectively. In-vitro drug release study data, stated that the optimum drug release was found in an acidic environment at pH 4.0, that showed 94.21% drug release after 16 hours and it proves that optimized formulation FA-SLNs will gave the sustained and better release in tumor tissue that owing acidic environment because of the angiogenesis process. In this research paper, different formulation parameters, found to influence fabrication of drug into Solid lipid nanoparticles, were optimized for high entrapment efficiency and drug loading. The most important parameters were drug:lipid ratio, drug:polymer ratio and lipid: surfactant ratio. Higher in-vitro drug release was observed in pH 4 as compared to the pH 7.4. These result data concludes that FA-SLNs formulation was successfully prepared, optimized and characterized.
{"title":"Folate conjugated solid lipid nanoparticle: formulation development, optimization and characterization","authors":"Vaibhav Rajoriya, Varsha Kashaw, S. Kashaw","doi":"10.2174/2468187311666211201111858","DOIUrl":"https://doi.org/10.2174/2468187311666211201111858","url":null,"abstract":"\u0000\u0000 The current paper represents the development, optimization, and characterization of paclitaxel-loaded folate conjugated solid lipid nanoparticles (FA-SLNs). \u0000\u0000\u0000\u0000\u0000 The ligand (FA-SLNs) conjugated and non-conjugated SLNs (PTX-SLNs) were prepared by hot homogenization method. Both of the formulations (FA-SLNs and PTX-SLNs) were optimized with various parameters i.e. drug loading, stirring time, stirring speed, particle size, and polydispersity index, and characterized. The in-vitro drug release study was performed in different pH environments by using the dialysis bag method. The surface morphology and particle size were determined through scanning electron micorscopy and Transmission Electron Microscopy respectively, The SLNs formulations were also evaluated for the stability study. \u0000\u0000\u0000\u0000\u0000The particle size of PTX-SLNs and FA-SLNs was determined and found to be 190.1±1.9 and 231.3±2.3 nm respectively. The surface morphology of the SLNs indicates that the prepared formulations are round-shaped and show smooth surfaces. The TEM study indicated that particles were in the range of 100-300 nm. The entrapment efficiency and drug loading capacity of FA-SLNs were found to be 79.42±1.6% and 17.3±1.9%, respectively. In-vitro drug release study data, stated that the optimum drug release was found in an acidic environment at pH 4.0, that showed 94.21% drug release after 16 hours and it proves that optimized formulation FA-SLNs will gave the sustained and better release in tumor tissue that owing acidic environment because of the angiogenesis process. \u0000\u0000\u0000\u0000\u0000 In this research paper, different formulation parameters, found to influence fabrication of drug into Solid lipid nanoparticles, were optimized for high entrapment efficiency and drug loading. The most important parameters were drug:lipid ratio, drug:polymer ratio and lipid: surfactant ratio. Higher in-vitro drug release was observed in pH 4 as compared to the pH 7.4. These result data concludes that FA-SLNs formulation was successfully prepared, optimized and characterized.\u0000\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47456731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-21DOI: 10.2174/246818731102210809145450
U. Saxena, M. Rajadurai, S. Basaveni, Swapna Yellanki, Raghavender Medishetti, Aarti Sevilimedu, P. Kulkarni
Due to an editorial oversight, we would like to apologize for an error that occurred in the print version of an article entitled “Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a Zebrafish Model, 2019, 9(2), 173-181 [1]. It was published as a case report; the article type has been changed to research article now. The original article can be found online at https://doi.org/10.2174/2468187308666180925143701
{"title":"Corrigendum to: Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a Zebrafish Model","authors":"U. Saxena, M. Rajadurai, S. Basaveni, Swapna Yellanki, Raghavender Medishetti, Aarti Sevilimedu, P. Kulkarni","doi":"10.2174/246818731102210809145450","DOIUrl":"https://doi.org/10.2174/246818731102210809145450","url":null,"abstract":"\u0000\u0000Due to an editorial oversight, we would like to apologize for an error that occurred in the print version of an article entitled\u0000“Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a\u0000Zebrafish Model, 2019, 9(2), 173-181 [1]. It was published as a case report; the article type has been changed to research article\u0000now.\u0000\u0000The original article can be found online at https://doi.org/10.2174/2468187308666180925143701\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46813001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-31DOI: 10.2174/2468187309666190906121924
López-Goerne Tessy, Ramírez-Olivares Paola, Armando Pérez-Dávalos Luis, A. Javier, Reyes-González Jesús, Zatta Simone Meneghetti, Murad Neif, Alves Beatriz da Costa Aguiar, Azzalis Ligia Ajaime, Junqueira Virginia Berlanga Campos, Rocha Roberto Odebrecht, Bacci, Marcelo Rodrigues, Feder David, Chagas Antonio Carlos Palandri, Adami Fernando, Fonseca Fernando Luiz Affonso, Chauhan Ritika, Chauhan Vinita, Sonkar Priyanka, Kumar Dhaked Ram, Avenoso Angela, Bruschetta Giuseppe, DAscola Angela, Scuruchi Michele, Mandraffino Giuseppe, Saitta Antonino, Campo Salvatore, M. Giuseppe, Li Tianzhong, Yang Mengsu, M. Madhumalini, Devi T. Meera, Azizi Mahsa, Rahimifard Nahid, Bahari Gholamreza, Mehdi Hashemi Seyed, Hashemi Mohammad, Li Zheng, Zhang Li-ping, Du Lei, Dong Weichao, S. Hexu, Shi Jijun, Zhang Chunyuan, Cao Yongjun, Qu Xinyuan, Liu Hui-Hui, You Shoujiang, Jin Xu, Yilin Guo
Diabetes mellitus is one of the most important health issues worldwide. The rising incidence of the disease has resulted in a parallel increase of complications such as diabetic foot ulcers (DFU). It is estimated that 25% of patients with diabetes will develop foot ulcers over a lifetime. In Mexico, this lifetime incidence is about 40% to 50%, and 20% of the cases will require amputations. DFU can result in staggering financial burdens for the healthcare system and the patient. Therapies that promote rapid and complete healing and reduce the need for expensive surgical procedures would impact these costs substantially. Cu/TiO2–SiO2 nanoparticles were synthesized by T. López et al. sol-gel patented method. After synthesis, they were characterized using transmission electron microscopy (TEM) and X-ray diffraction. Then, they were embedded in a polymeric gel matrix. The Cu/TiO2–SiO2 nanogel was used as conservative therapy for a chronic non-healing DFU on a 62-year old female with several comorbidities and chronic complications of diabetes. Wound debridement was performed prior to nanogel administration. The nanogel was applied over the ulcer on alternate days for an initial period of 2 weeks and then continued for 10 months. Significant improvement was observed in the wound healing process since the first applications. The infection was limited and tissue regeneration was enhanced until complete healing of the ulcer. Cu/TiO2–SiO2 nanogel therapy enhanced reepithelialization and healing of the DFU. The successful outcome allowed to avoid the amputation that was proposed for the patient.
{"title":"Catalytic Nanomedicine. Cu/TiO2–SiO2 Nanoparticles as Treatment of Diabetic Foot Ulcer: A Case Report","authors":"López-Goerne Tessy, Ramírez-Olivares Paola, Armando Pérez-Dávalos Luis, A. Javier, Reyes-González Jesús, Zatta Simone Meneghetti, Murad Neif, Alves Beatriz da Costa Aguiar, Azzalis Ligia Ajaime, Junqueira Virginia Berlanga Campos, Rocha Roberto Odebrecht, Bacci, Marcelo Rodrigues, Feder David, Chagas Antonio Carlos Palandri, Adami Fernando, Fonseca Fernando Luiz Affonso, Chauhan Ritika, Chauhan Vinita, Sonkar Priyanka, Kumar Dhaked Ram, Avenoso Angela, Bruschetta Giuseppe, DAscola Angela, Scuruchi Michele, Mandraffino Giuseppe, Saitta Antonino, Campo Salvatore, M. Giuseppe, Li Tianzhong, Yang Mengsu, M. Madhumalini, Devi T. Meera, Azizi Mahsa, Rahimifard Nahid, Bahari Gholamreza, Mehdi Hashemi Seyed, Hashemi Mohammad, Li Zheng, Zhang Li-ping, Du Lei, Dong Weichao, S. Hexu, Shi Jijun, Zhang Chunyuan, Cao Yongjun, Qu Xinyuan, Liu Hui-Hui, You Shoujiang, Jin Xu, Yilin Guo","doi":"10.2174/2468187309666190906121924","DOIUrl":"https://doi.org/10.2174/2468187309666190906121924","url":null,"abstract":"\u0000\u0000Diabetes mellitus is one of the most important health issues\u0000worldwide. The rising incidence of the disease has resulted in a parallel increase of complications\u0000such as diabetic foot ulcers (DFU). It is estimated that 25% of patients with diabetes\u0000will develop foot ulcers over a lifetime. In Mexico, this lifetime incidence is about\u000040% to 50%, and 20% of the cases will require amputations. DFU can result in staggering\u0000financial burdens for the healthcare system and the patient. Therapies that promote rapid\u0000and complete healing and reduce the need for expensive surgical procedures would impact\u0000these costs substantially.\u0000\u0000\u0000\u0000Cu/TiO2–SiO2 nanoparticles were synthesized by T. López et al. sol-gel patented\u0000method. After synthesis, they were characterized using transmission electron microscopy\u0000(TEM) and X-ray diffraction. Then, they were embedded in a polymeric gel matrix.\u0000The Cu/TiO2–SiO2 nanogel was used as conservative therapy for a chronic non-healing\u0000DFU on a 62-year old female with several comorbidities and chronic complications of diabetes.\u0000Wound debridement was performed prior to nanogel administration. The nanogel\u0000was applied over the ulcer on alternate days for an initial period of 2 weeks and then continued\u0000for 10 months.\u0000\u0000\u0000\u0000Significant improvement was observed in the wound healing process since the\u0000first applications. The infection was limited and tissue regeneration was enhanced until\u0000complete healing of the ulcer.\u0000\u0000\u0000\u0000Cu/TiO2–SiO2 nanogel therapy enhanced reepithelialization and healing of\u0000the DFU. The successful outcome allowed to avoid the amputation that was proposed for\u0000the patient.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2468187309666190906121924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43647373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-31DOI: 10.2174/2468187310999201023151231
Harshita Gupta, Rutu Panchal, P. Mehta, R. Momin
There are numerous unavoidable hurdles encountered by scientists to achieve an ideal drug delivery. Among them, the high-water solubility of a therapeutic molecule has been observed as a chief pausing factor that diminishes the biological stay and shortens the half-life of a drug. The ramification of this occurs that patients have to take medications multiple times in a single day to maintain the drug-plasma concentration. These consequences lead to poor pharmacological responses and ultimately do not add any significant outcomes in the betterment of patient’s health. A similar phenomenon has been observed with the delivery of some potent Anti-Parkinson’s medications, for instance, Pramipexole. The current research is aimed at developing the biological residue of Pramipexole Hydrochloride (PRP) based on the counter ion technology that has provided a sojourn release of PRP by retarding the aqueous solubility, which is further characterized using the dissolution study. Initially, the molar ratio of PRP and the selected counter ion, i.e., Disodium Pamoate (NaPAM), was quantified to produce the stable salt. Thereafter, the salt formation was preceded by the precipitation method and this primarily obtained salt is called microcrystals. In the next stage, the microcrystals were characterized by numerous analytical tools such as Differential Scanning Calorimetry (DSC), melting point, and Mass Spectrometry (MS). On the other hand, Ultraviolet Spectroscopy (UV) was used for the simultaneous determination of PRP and NaPAM in the formed salt. After this, the development of nanocrystals from microcrystals was carried out using high-shear homogenization (HSH) with the aid of α-Tocopherol Polyethylene Glycol 1000 Succinate (TPGS), employed as a stabilizer. The preceding step was performed by analyzing the particle size. Following this, an in vitro dissolution study was planned using a dialysis bag system (at 6.8 pH buffer) along with vehicle development and characterization being taken into consideration. An equimolar ratio (1:1) of PRP and counter ion stipulated the complete reaction occurred among them and then considering this ratio (based on the percent loading efficiency (%LE) and complexation efficiency) (%CE), salt preparation was done. Upon analysis of the developed salt (microcrystal), satisfactory outcomes have assured the complete and compatible salt formation. Besides it, simultaneous estimation certified that the presence of PRP and NaPAM in the formulation does not affect each other, qualitatively and quantitatively. Apart from that, the particle size of these nanocrystals was also found in the acceptable range. Furthermore, Pramipexole Pamoate Nanocrystals Salt (PPNS) was formulated, and in vitro dissolution study showed that PPNS was significantly able to extend the release (93.87 % release, i.e., sustainable) up to 48 hours as compared to the standard PRP. Additionally, the developed vehicle was found suitable and stable, both at room
{"title":"Development of Pramipexole Hydrochloride Nanocrystals and their Characterization based on In vitro Dissolution Studies","authors":"Harshita Gupta, Rutu Panchal, P. Mehta, R. Momin","doi":"10.2174/2468187310999201023151231","DOIUrl":"https://doi.org/10.2174/2468187310999201023151231","url":null,"abstract":"\u0000\u0000There are numerous unavoidable hurdles encountered by scientists to\u0000achieve an ideal drug delivery. Among them, the high-water solubility of a therapeutic molecule has\u0000been observed as a chief pausing factor that diminishes the biological stay and shortens the half-life\u0000of a drug. The ramification of this occurs that patients have to take medications multiple times in a\u0000single day to maintain the drug-plasma concentration. These consequences lead to poor pharmacological\u0000responses and ultimately do not add any significant outcomes in the betterment of patient’s\u0000health. A similar phenomenon has been observed with the delivery of some potent Anti-Parkinson’s\u0000medications, for instance, Pramipexole. The current research is aimed at developing the biological\u0000residue of Pramipexole Hydrochloride (PRP) based on the counter ion technology that has provided a\u0000sojourn release of PRP by retarding the aqueous solubility, which is further characterized using the\u0000dissolution study.\u0000\u0000\u0000\u0000 Initially, the molar ratio of PRP and the selected counter ion, i.e., Disodium\u0000Pamoate (NaPAM), was quantified to produce the stable salt. Thereafter, the salt formation was preceded\u0000by the precipitation method and this primarily obtained salt is called microcrystals. In the next\u0000stage, the microcrystals were characterized by numerous analytical tools such as Differential Scanning\u0000Calorimetry (DSC), melting point, and Mass Spectrometry (MS). On the other hand, Ultraviolet\u0000Spectroscopy (UV) was used for the simultaneous determination of PRP and NaPAM in the\u0000formed salt. After this, the development of nanocrystals from microcrystals was carried out using\u0000high-shear homogenization (HSH) with the aid of α-Tocopherol Polyethylene Glycol 1000 Succinate\u0000(TPGS), employed as a stabilizer. The preceding step was performed by analyzing the particle size.\u0000Following this, an in vitro dissolution study was planned using a dialysis bag system (at 6.8 pH buffer)\u0000along with vehicle development and characterization being taken into consideration.\u0000\u0000\u0000\u0000An equimolar ratio (1:1) of PRP and counter ion stipulated the complete reaction occurred\u0000among them and then considering this ratio (based on the percent loading efficiency (%LE) and\u0000complexation efficiency) (%CE), salt preparation was done. Upon analysis of the developed salt (microcrystal),\u0000satisfactory outcomes have assured the complete and compatible salt formation. Besides\u0000it, simultaneous estimation certified that the presence of PRP and NaPAM in the formulation does not\u0000affect each other, qualitatively and quantitatively. Apart from that, the particle size of these nanocrystals\u0000was also found in the acceptable range. Furthermore, Pramipexole Pamoate Nanocrystals Salt\u0000(PPNS) was formulated, and in vitro dissolution study showed that PPNS was significantly able to\u0000extend the release (93.87 % release, i.e., sustainable) up to 48 hours as compared to the standard PRP.\u0000Additionally, the developed vehicle was found suitable and stable, both at room","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43575912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-31DOI: 10.2174/2468187310999201105143429
Amandeep Singh, Deepak Negi, Simranjeet Kaur, S. Bhattachary, Gurmeet Singh
Cancer is a pivotal disease, which is a serious concern towards scientific research. In the recent era of scientific discovery and innovation, probiotics have been proposed as a new preventive and therapeutic option in therapy and to control cancer growth. Probiotics may thus offer a new way in research to investigate active compounds in different probiotic strains having anticancer features. Studies in laboratory animals and cell lines with respect to cancer treatments are encouraging. With rare conventional treatments, the need for new alternatives as the transportation of chemotherapeutic agents by nanocarriers using nanotechnology is one such approach. This review considers various drug delivery systems used in the therapy of cervical cancer, such as dendrimers, liposomes and nanoparticles. These drug delivery systems assist in the improvement of pharmacological activity, solubility, bioavailability and, thus, facilitating new innovative therapeutic technologies. This review summarizes the application of nanotechnology and probiotics in the treatment of cervical cancer.
{"title":"Fundamentals of Nanocarriers and Probiotics in the Treatment of Cervical Cancer","authors":"Amandeep Singh, Deepak Negi, Simranjeet Kaur, S. Bhattachary, Gurmeet Singh","doi":"10.2174/2468187310999201105143429","DOIUrl":"https://doi.org/10.2174/2468187310999201105143429","url":null,"abstract":"\u0000\u0000Cancer is a pivotal disease, which is a serious concern towards scientific research.\u0000In the recent era of scientific discovery and innovation, probiotics have been proposed\u0000as a new preventive and therapeutic option in therapy and to control cancer growth.\u0000Probiotics may thus offer a new way in research to investigate active compounds in different\u0000probiotic strains having anticancer features. Studies in laboratory animals and cell lines\u0000with respect to cancer treatments are encouraging. With rare conventional treatments, the\u0000need for new alternatives as the transportation of chemotherapeutic agents by nanocarriers\u0000using nanotechnology is one such approach. This review considers various drug delivery\u0000systems used in the therapy of cervical cancer, such as dendrimers, liposomes and nanoparticles.\u0000These drug delivery systems assist in the improvement of pharmacological activity,\u0000solubility, bioavailability and, thus, facilitating new innovative therapeutic technologies.\u0000This review summarizes the application of nanotechnology and probiotics in the treatment\u0000of cervical cancer.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45263451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：